Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2003

View Archived Issues

Company Profile: Transition Therapeutics

Genzyme to acquire SangStat

Akina develops oral drug delivery technology

Two novel series of VR1 antagonists for urinary incontinence, pain, etc.

Galderma presents new PPARgamma agonists with potential in dermatological disorders

BMS claims new IMPDH inhibitors and their use in recent patent

Aventis scientists prepare new antibacterial streptogramin derivatives

Novel alpha7 nAChR agonists in early development at Bayer

New MMP, TACE and/or aggrecanase inhibitors covered by BMS patent

R&D highlights at Neurosearch

Once-daily Adderall XR formulation may be a useful treatment option in children with ADHD

FTC clears Biogen/Idec merger

NexMed enters NexACT R&D agreement for asthma

Novel 5-HT7 receptor agonist modulates REM sleep

Human Genome Sciences and Genentech enter licensing agreement

17-AAG combination regimens studied in new phase Ib trials

Neurosciences Australia and CSIRO form R&D partnership in brain disorders

First pivotal exenatide study produces positive results

MPC-7869 reduces Abeta42 levels more effectively than select NSAIDs

Exelixis reports quarterly progress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...